TTRX (TTRX) reported R&D of $109.43K in Q1 2026.

How has TTRX's R&D changed year-over-year?

TTRX's R&D increased by 1081.9% year-over-year, from $9.26K to $109.43K.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

TTRX TTRX R&D

R&D at other companies

Regeneron PharmaceuticalsREGN

$1.54B+16.3%

Bausch Health CompaniesBHC

$163M+14.0%

Journey Medical CorporationDERM

$154K-29.4%

PTH

Pelthos Therapeutics Inc.PTHS

$186K-4.1%

Celldex TherapeuticsCLDX

$73M+38.7%

Arcutis Biotherapeutics, Inc.ARQT

$30.63M+74.6%

Other financials

Income statement

See full

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

See full

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

See full

Operating cash flow-$1.6M-448%

Valuation

See full

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

See full

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TTRX's R&D?: TTRX (TTRX) reported R&D of $109.43K in Q1 2026.
How has TTRX's R&D changed year-over-year?: TTRX's R&D increased by 1081.9% year-over-year, from $9.26K to $109.43K.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.